Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. For more information, please visit www.celgene.com. Follow Celgene on Social Media: @Celgene, Pinterest, LinkedIn, Facebook and YouTube.
Company profile
Ticker
CELG
Exchange
Website
CEO
Mark J. Alles
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
Corporate docs
IRS number
222711928
CELG stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
13 Dec 19
S-4 POS
Post-effective amendment to a S-4EF registration statement
9 Dec 19
S-4 POS
Post-effective amendment to a S-4EF registration statement
9 Dec 19
S-4 POS
Post-effective amendment to a S-4EF registration statement
9 Dec 19
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Dec 19
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Dec 19
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Dec 19
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Dec 19
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Dec 19
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Dec 19
Latest ownership filings
Institutional ownership, Q3 2022
| 13F holders | Current |
|---|---|
| Total holders | 0 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 0.00 |
| Total shares | 0.00 |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|